A Phase 3 interventional study of Levofloxacin + dexamethasone followed by dexamethasone and Tobramycin + Dexamethasone in Cataract, sponsored by NTC srl. Completed at 57 sites in Italy. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2020-08-18.
Sponsored by NTC srl · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing dexamethasone in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Dexamethasone · Cataract.
Among the 34 studies testing dexamethasone in Cataract, this one is the 2nd largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 3, and was the 8th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →1 of the 34 studies testing dexamethasone in Cataract is open now, in 1 country. Recruiting first, the newest first:
Laboratorios Sophia S.A de C.V. · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 10 · Phase 4 18
First in 2004; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 808 is above the median of 79 across 1,094 interventional studies indexed under Cataract.
Median enrollment 50 across the 34 interventional studies. Of the 25 that completed or were terminated, 8 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 34 have an industry lead sponsor. The 10 most frequent:
NTC srl is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
NTC srl has 2 studies filed under Cataract — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 34 studies testing dexamethasone in Cataract, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate the non-inferiority of the study treatment (combined levofloxacin + dexamethasone eye drops) followed by dexamethasone eye drops alone vs. standard treatment in the prevention and treatment of postoperative ocular inflammation and prevention of infection.
In clinical practice, topical treatment following cataract surgery is frequently administered using a combination between an antibiotic and a corticosteroid to promote patient adherence to therapy and to obtain both prevention of infection and treatment of post-surgical inflammation.
The combination of tobramycin and dexamethasone is among the most widely used combinations, however, treatment duration and the need for tapering posology over several weeks may favour the development of bacterial resistance. The study treatment associating a broad-spectrum antibiotic with a highly effective corticosteroid that can be used for a short period of time (one week) is therefore of considerable interest.
The aim of this study is to evaluate the non-inferiority of the study treatment, used for a limited period of time and followed by dexamethasone alone, compared to standard treatment in preventing and treating ocular inflammation and in preventing post-operative infection while limiting the emergence of antibiotic resistance.
Inclusion Criteria prior to surgery:
Female patients must be , surgically sterile or must agree to use an effective method of
Inclusion criteria following surgery:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).
Drug: Levofloxacin + dexamethasone followed by dexamethasone
Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).
Drug: Tobramycin + Dexamethasone
Drug pages: Levofloxacin · Dexamethasone
Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.
Also known as: Levofloxacin + dexamethasone followed by Maxidex
Drug pages: Tobramycin · Dexamethasone
Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.
Also known as: Tobradex
Number of Participants Without Signs of Anterior Chamber Inflammation
The number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses has been tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS \> - Δ. Where πT and πS are the number of participants without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.
Time frame: Day 15
Number of Participants With Endophthalmitis
The number of participants with endophthalmitis after administration of study treatment in the study was assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs.
Time frame: Day 4, 8, 15
Number of Participants Without Signs of Anterior Ocular Chamber Inflammation
Number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0).
Time frame: Day 0 (screening), 4, 8
Conjunctival Hyperemia
Conjunctival hyperemia was evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable).
Time frame: Day 4, 8, 15
Total Ocular Symptoms Score (TOSS)
The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. A score was given in the presence of symptoms: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
Time frame: Day 4, 8, 15
Ocular Pain/Discomfort: 4-point Scale
Overall ocular pain and discomfort was evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).
Time frame: Day 4, 8, 15
Use of Rescue Therapy
All rescue therapy used following cataract surgery is to be reported at all visits.
Time frame: During all the treatment until day 15
Intraocular Pressure (IOP)
IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg.
Time frame: At day 0 (screening) and at day 4, 8, 15
Visual Acuity
Visual acuity was assessed as per local clinical practice, i.e. with the Snellen (feet) or the ETDRS (meter) chart. Visual acuity was then analysed using decimal unit. Decimal score is the decimal expression of the Snellen (feet) or the ETDRS (meter) charts in which the numerator indicates the distance from the chart and the denominator indicates the size of the smallest line that can be read. Decimal values were provided directly from the investigator or computed as a result of the Snellen or ETDRS fraction. Generally decimal values from 0.01 to 0.10 indicate severe vision loss; decimal values from 0.125 to 0.25 indicate moderate vision loss; decimal values from 0.32 to 0.63 indicate mild vision loss; decimal values from 0.8 to 1.6 indicate normal vision. Lower decimal values correspond to a reduced visual acuity and worst outcomes, while higher decimal values indicate an improved visual acuity and better outcomes.
Time frame: At day 0 (screening) and at day 15
Adverse Events
Adverse events were described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and were presented by treatment group.
Time frame: During all the treatment until day 15
Global Evaluation of Local Tolerability
Global evaluation was evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability.
Time frame: Day 4, 8, 15
Burning, Stinging, Blurred Vision
Burning, stinging, blurred vision were evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
Time frame: Day 4, 8, 15
Assessment of Patient Diary (Compliance)
Treatment compliance is derived from the number of instillations each day during the study treatment exposure
Time frame: Day 15
Study period: * Date of first enrolment: 03.09.2018 * Date study finalized (LPLV): 19.12.2018 Study centers: * 42 centers in Italy * 4 centers in Spain * 4 centers in Russia * 1 center in Germany
| Milestone | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Started | 403 | 405 |
| Received at least one treatment | 395 | 393 |
| Completed | 388 | 388 |
| Not completed | 15 | 17 |
| Withdrew: Not treated | 8 | 12 |
| Withdrew: Treatment and study discontinued | 6 | 2 |
| Withdrew: Treatment discontinued + study completed | 1 | 3 |
The number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses has been tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS \> - Δ. Where πT and πS are the number of participants without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.
| Participants | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Number of participants without signs | 376 | 373 |
| Number of participants with signs | 19 | 20 |
The number of participants with endophthalmitis after administration of study treatment in the study was assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs.
| Participants | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Visit 3 - Day 4: no diagnosis of endophthalmitis | 393 | 393 |
| Visit 4 - Day 8: no diagnosis of endophthalmitis | 391 | 393 |
| Visit 5 - Day 15: no diagnosis of endophthalmitis | 389 | 391 |
Number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0).
| Participants | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Visit 1 - Screening — Number of participants without signs | 395 | 393 |
| Visit 1 - Screening — Number of participants with signs | 0 | 0 |
| Visit 3 - Day 4 — Number of participants without signs | 289 | 302 |
| Visit 3 - Day 4 — Number of participants with signs | 106 | 91 |
| Visit 4 - Day 8 — Number of participants without signs | 338 | 341 |
| Visit 4 - Day 8 — Number of participants with signs | 57 | 52 |
Conjunctival hyperemia was evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable).
| Participants | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Visit 3 - Day 4 — Score=0 | 337 | 323 |
| Visit 3 - Day 4 — Score>0 | 58 | 70 |
| Visit 4 - Day 8 — Score=0 | 348 | 358 |
| Visit 4 - Day 8 — Score>0 | 47 | 35 |
| Visit 5 - Day 15 — Score=0 | 371 | 375 |
| Visit 5 - Day 15 — Score>0 | 24 | 18 |
The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. A score was given in the presence of symptoms: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
| score on a scale | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Visit 3 - Day 4 | 0.29 ± 0.63 | 0.37 ± 0.73 |
| Visit 4 - Day 8 | 0.28 ± 0.67 | 0.26 ± 0.62 |
| Visit 5 - Day 15 | 0.17 ± 0.49 | 0.17 ± 0.59 |
Overall ocular pain and discomfort was evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).
| Participants | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Visit 3 - Day 4: Presence/absence of ocular pain — Score=0 | 360 | 361 |
| Visit 3 - Day 4: Presence/absence of ocular pain — Score>0 | 35 | 32 |
| Visit 4 - Day 8: Presence/absence of ocular pain — Score=0 | 366 | 366 |
| Visit 4 - Day 8: Presence/absence of ocular pain — Score>0 | 29 | 27 |
| Visit 5 - Day 15: Presence/absence of ocular pain — Score=0 | 377 | 373 |
| Visit 5 - Day 15: Presence/absence of ocular pain — Score>0 | 18 | 20 |
All rescue therapy used following cataract surgery is to be reported at all visits.
| Participants | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Patients with rescue therapy | 392 | 392 |
| Patients with no rescue therapy | 3 | 1 |
IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg.
| mmHg | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Visit 1 - Screening | 15.16 ± 2.48 | 15.12 ± 2.41 |
| Visit 3 - Day 4 | 14.26 ± 2.73 | 14.49 ± 2.81 |
| Visit 4 - Day 8 | 14.29 ± 2.51 | 14.45 ± 3.03 |
| Visit 5 - Day 15 | 14.45 ± 2.65 | 14.37 ± 2.47 |
Visual acuity was assessed as per local clinical practice, i.e. with the Snellen (feet) or the ETDRS (meter) chart. Visual acuity was then analysed using decimal unit. Decimal score is the decimal expression of the Snellen (feet) or the ETDRS (meter) charts in which the numerator indicates the distance from the chart and the denominator indicates the size of the smallest line that can be read. Decimal values were provided directly from the investigator or computed as a result of the Snellen or ETDRS fraction. Generally decimal values from 0.01 to 0.10 indicate severe vision loss; decimal values from 0.125 to 0.25 indicate moderate vision loss; decimal values from 0.32 to 0.63 indicate mild vision loss; decimal values from 0.8 to 1.6 indicate normal vision. Lower decimal values correspond to a reduced visual acuity and worst outcomes, while higher decimal values indicate an improved visual acuity and better outcomes.
| decimal score | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Visit 1 - Screening | 0.41 ± 0.23 | 0.41 ± 0.26 |
| Visit 5 - Day 15 | 0.88 ± 0.19 | 0.89 ± 0.17 |
Adverse events were described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and were presented by treatment group.
| Participants | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Patients with TEAEs | 56 | 51 |
| Patients with serious TEAEs | 4 | 2 |
| Patients with TEAEs suspected to be study related | 26 | 26 |
| Patients with TEAEs leading to discontinuation | 4 | 3 |
| Patients with fatal TEAEs | 1 | 0 |
| Patients with severe TEAEs | 3 | 0 |
Global evaluation was evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability.
| score on a scale | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Visit 3 - Day 4 | 0.03 ± 0.21 | 0.01 ± 0.09 |
| Visit 4 - Day 8 | 0.01 ± 0.11 | 0.03 ± 0.19 |
| Visit 5 - Day 15 | 0.02 ± 0.15 | 0.02 ± 0.13 |
Burning, stinging, blurred vision were evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
| score on a scale | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| Burning: visit 3 - day 4 | 0.08 ± 0.27 | 0.09 ± 0.29 |
| Burning: visit 4 - day 8 | 0.06 ± 0.24 | 0.11 ± 0.35 |
| Burning: visit 5 - day 15 | 0.07 ± 0.29 | 0.07 ± 0.27 |
| Stinging: visit 3 - day 4 | 0.05 ± 0.23 | 0.04 ± 0.20 |
| Stinging: visit 4 - day 8 | 0.07 ± 0.29 | 0.07 ± 0.26 |
| Stinging: visit 5 - day 15 | 0.06 ± 0.26 | 0.04 ± 0.20 |
| Blurred vision: visit 3 - day 4 | 0.06 ± 0.27 | 0.05 ± 0.23 |
| Blurred vision: visit 4 - day 8 | 0.06 ± 0.25 | 0.04 ± 0.22 |
| Blurred vision: visit 5 - day 15 | 0.03 ± 0.20 | 0.01 ± 0.11 |
Treatment compliance is derived from the number of instillations each day during the study treatment exposure
| Participants | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| No missed dose | 332 | 332 |
| One missed dose per day or three missed doses per | 59 | 57 |
| > 1 missed dose per day or > 3 missed doses per we | 4 | 4 |
Collected over From baseline to the end of the treatment, corresponding to 15 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Levofloxacin + Dexamethasone Followed by Dexamethasone | 1/395 (0.3%) | 4/388 (1%) | 0/395 (0%) |
| Tobramycin + Dexamethasone | 0/393 (0%) | 2/388 (0.5%) | 0/393 (0%) |
| Event | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone |
|---|---|---|
| FallInjury, poisoning and procedural complications | 2/388 | 1/388 |
| Myocardial InfarctionCardiac disorders | 1/388 | 1/388 |
| Retinal DetachmentEye disorders | 1/388 | 0/388 |
The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)
| Age, Categorical(Participants) | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 70 | 71 | 141 |
| >=65 years | 325 | 322 | 647 |
| Age, Continuous(years) | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone | Total |
|---|---|---|---|
| Mean | 72.12 ± 8.55 | 71.84 ± 8.64 | 71.98 ± 8.59 |
| Sex: Female, Male(Participants) | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone | Total |
|---|---|---|---|
| Female | 229 | 239 | 468 |
| Male | 166 | 154 | 320 |
| Race (NIH/OMB)(Participants) | Levofloxacin + Dexamethasone Followed by Dexamethasone | Tobramycin + Dexamethasone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 |
| Black or African American | 0 | 0 | 0 |
| White | 393 | 391 | 784 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2018 to primary completion in Dec 2018, 3 months.
Results were first posted in Aug 2020, 1 year 7 months after primary completion.
Of 23 industry-sponsored phase 3 interventional studies under Cataract, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 15. This study's 3 months is below that.
Counting every sponsor, half of 31 studies reached it within 13 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Levofloxacin · Dexamethasone
NTC srl